Alarin

Quick links to important sections

Alarin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alarin

Quick Facts

Property Description
Active ingredient Loratadine
Form Tablet, Syrup, Oral solution
Pharmacological class Second-generation Histamine H1 Receptor Antagonist
Common use (General Purpose) Anti-allergic action
Origin Synthetic (Piperidine derivative)

Alarin: Classification and Active Component (Loratadine)

Alarin is a synthetic pharmaceutical preparation containing the single active ingredient Loratadine. It is classified as a second-generation antihistamine, belonging to the pharmacological group of Histamine H1 receptor antagonists.

The core chemical entity, Loratadine, is a Piperidine derivative that possesses a distinct tricyclic structure. Pharmacological properties support its role as an H1 antagonist, which functions by blocking the pathway responsible for triggering allergic responses. This structural design is a key differentiation point from older antihistamine compounds.

What is the General Purpose of Alarin?

The general purpose of Alarin is to achieve sustained anti-allergic action through the suppression of systemic histamine effects, providing support in scenarios involving unwanted immune system responses.

This action is rooted in selective peripheral H1 antagonism. The medication is characterized as a non-sedating antihistamine due to the molecular structure's characteristic of minimal blood-brain barrier penetration. This profile allows for systemic use without the significant cognitive effects typically associated with earlier generations of antihistamines.

Forms of Alarin for Systemic Use

Alarin is intended for systemic use and is supplied as a single active ingredient product. It is available in multiple forms suitable for oral administration: specifically a tablet, a liquid syrup, and an oral solution. The availability of these dosage forms provides various options for the intake method. The liquid formulations utilize an aqueous base for delivery, while the solid medication format relies on solid excipients.

What side effects are possible with Alarin?

Official Safety Profile and Adverse Reactions

Alarin's safety profile is documented in official regulatory sources, which classify possible adverse reactions across standard frequency categories and System-Organ Classes. The most common effects reported in regulatory studies primarily involve the Nervous System and general well-being.

Frequency-Classified Adverse Reactions

Classification Example Adverse Reactions (SOC)
Common (may affect up to 1 in 10 people) Headache, Somnolence (drowsiness), Fatigue, Insomnia, Increased Appetite.
Very Rare (may affect up to 1 in 10,000 people) Dizziness, Tachycardia (rapid heartbeat), Nausea, Abnormal Hepatic Function (liver problems), Convulsion (seizure), Alopecia.
Not Known Weight Increased.

Serious adverse reactions are categorized as Very Rare in the official labeling. These include severe Hypersensitivity Reactions, such as Anaphylaxis and Angioedema, and Convulsion.

Population-Specific and Diagnostic Constraints

The regulatory documentation outlines specific safety considerations for certain individuals. Caution is advised for patients with severe hepatic impairment (severe liver problems). Additionally, individuals with Phenylketonuria (PKU) should note that some oral formulations may contain aspartame. The medication must be discontinued at least 48 hours prior to allergy skin testing, as the drug may interfere with the test results and prevent an accurate diagnosis. The official profile also includes a high-level safety statement regarding the potential for elevated Loratadine plasma levels when taken with certain enzyme-inhibiting medicines.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Alarin (Loratadine) is derived exclusively from regulatory documents and defines the specific clinical manifestations and mandated emergency actions. All individuals who suspect an overdose must seek medical help or contact a Poison Control Center right away, as officially stated in the drug labeling.


Documented Overdose Manifestations and Actions

Aspect Official Regulatory Statement
Documented Manifestations Symptoms reported include somnolence (drowsiness), headache, and a rise in tachycardia (rapid heart rate). An increased occurrence of anticholinergic symptoms is also documented.
Affected Systems Regulatory documents specify effects on the Central Nervous System and the Cardiovascular System.
Management Measures General symptomatic and supportive measures must be instituted promptly and maintained. Interventions such as activated charcoal administration or gastric lavage may be considered.
Antidote Status No specific antidote has been identified or is known for Loratadine overdose.
Monitoring Constraint The drug is not removed by haemodialysis, which is a critical constraint for advanced medical management and monitoring.
Population Note In the management of overdose for children, the use of physiologic saline solution is specified as the lavage solution of choice.

The regulatory profile mandates that medical monitoring of the patient be continued after initial emergency treatment, emphasizing a supportive care approach. Since no specific antidote is available, management focuses on the removal of unabsorbed drug and sustained care for the documented physiological manifestations.

Therapeutic Uses of Alarin

What Alarin Treats: Main Uses and Benefits

Alarin is commonly used across conditions involving episodic or fluctuating manifestations associated with allergic disease, providing support that helps ease the overall symptom burden. It is considered relevant in contexts marked by increased discomfort due to hay fever and other allergic manifestations.

It is applied in addressing conditions such as Seasonal and Perennial Allergic Rhinitis, as well as the symptomatic relief of Chronic Idiopathic Urticaria (hives). It is applied in addressing symptom clusters that may become intense or disruptive, including sneezing, rhinorrhea (runny nose), nasal itching, irritating ocular manifestations, and pervasive skin pruritus (itching).

“Alarin is applied across domains where additional symptomatic support is needed, assisting with maintaining functional stability when symptoms interfere with routine activities.”

This offers symptomatic relief that may help patients cope more steadily with symptom fluctuations, particularly when symptoms interfere with daily routines. It is applied during phases of increased distress or discomfort and can contribute to improved comfort during periods of heightened symptoms.


Quick Fact: Symptomatic Support for Itching and Nasal Symptoms

Category Typical Symptom Benefit
Respiratory Sneezing, Runny Nose May assist with functional strain
Ocular Itchy, Watery Eyes Contributes to comfort
Cutaneous Itching (Pruritus), Hives Assists with stability

Regulatory References

  1. DailyMed - NIH Label for Loratadine

Eligibility and Restrictions for Use

Who Can and Cannot Use Alarin?

The eligibility for Alarin (Loratadine) is governed by official regulatory rules regarding age, physiological status, and pre-existing health conditions.

Eligibility Status Population/Condition
Contraindicated Documented hypersensitivity to the active substance, Loratadine, or to any other component of the formulation.
Use Not Established Children younger than two (2) years of age, as safety and efficacy have not been formally established.

Age-Group and Physiological Eligibility

Most adults and children six years and older are eligible for standard use. Use is established for children aged two to five years, often with specific liquid formulations as advised by the regulator. Use is not recommended during breast-feeding, as the substance passes into milk. While data is limited, use during pregnancy is advised to be avoided as a precautionary measure.

Restricted or Conditional Use

Eligibility is conditional for individuals with severe hepatic (liver) or renal (kidney) impairment. Regulatory labeling requires that these populations be considered for an extended administration interval due to potential reduced clearance. Furthermore, patients with Phenylketonuria (PKU) must avoid specific formulations (e.g., chewable tablets) that contain phenylalanine. Use must also be discontinued prior to skin allergy testing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents require specific constraints when using products containing Alarin's active ingredient, primarily to prevent serious health risks related to cumulative exposure or combined systemic effects.

Documented Interaction Constraints

Interacting Product Category Constraint or Requirement
Other Acetaminophen Products Do not combine. Co-administration with any other medicine (prescription or over-the-counter) containing acetaminophen is strictly prohibited to avoid accidental overdose and the resulting risk of severe liver damage.
Anticoagulants (e.g., Warfarin) Consult a Healthcare Professional. Individuals taking blood-thinning medicines, such as Warfarin, must consult a doctor or pharmacist prior to use, as the combination may increase the risk of bleeding.
Alcohol Consumption Consult a Healthcare Professional. Individuals who regularly consume three or more alcoholic drinks every day must consult a doctor before using this product. Concurrent use under these conditions significantly increases the risk of severe or possibly fatal liver damage.

These constraints establish the core interaction structure for the product, focusing on preventing cumulative toxicity and managing specific systemic drug-drug and drug-substance combinations that pose a heightened risk as documented in official government labeling.

Mechanism of Action

Alarin is a peptide antagonist that specifically targets the A1R receptor, which is expressed on the surface of osteoclast precursor cells. Upon binding, Alarin's inhibitory activity interrupts the NFATc1 signaling cascade, a pathway critical for the transcription factors required for osteoclast differentiation and maturation.

This interference with cellular signaling reduces the expression of key osteoclast activity markers, including tartrate-resistant acid phosphatase ( TRAP) and cathepsin K. This reduction leads to a marked decrease in the fusion and overall count of mature, active osteoclasts, resulting in a net decrease in bone resorption activity. The consequence is an altered equilibrium of bone matrix synthesis and degradation, shifting the balance toward reduced breakdown.

Dosage and Administration Information

How to Use Alarin — Administration Guidelines

This section outlines the parameters for the use and administration of Alarin, reflecting the established protocols for the medication.


Administration Scope

Administration Element Instruction
Route Oral (by mouth)
Form Film-Coated Tablet or Hard Capsule
Standard Dosing Starting dose: 150 mg once daily. Maximum daily dose: 600 mg.
Frequency Once daily or in two to three divided doses per day.
Timing May be taken with or without food.

Procedural and Patient-Specific Instructions

Special Administration Conditions

The tablet or capsule is intended to be swallowed whole; instructions indicate that the medication should not be chewed, crushed, or split before intake. Treatment discontinuation involves gradual tapering over a minimum of one week, as abrupt cessation is not recommended.

Population-Specific Dosing

Dosing adjustment is specified for patients with confirmed renal impairment (kidney issues), with dose levels determined by estimated creatinine clearance. Use is generally not indicated for pediatric patients (under 18 years) due to insufficient data regarding efficacy and safety in this population.

Missed Dose Rules

In the event of a missed dose of Alarin, the protocol is to skip the missed dose entirely. The regular schedule should be resumed at the next scheduled time. The dose should not be doubled to compensate for the one that was missed.

Recent Clinical Evidence

Alarin: Recent Clinical Evidence

Overview of the Research for Alarin

Research explores the active ingredient Loratadine in studies focused on conditions characterized by fluctuating or episodic manifestations. The evidence base primarily consists of numerous short-term Randomized Controlled Trials (RCTs), where the compound was examined against a placebo or another active therapy. This structure provides a foundation for understanding the context in which the compound was examined. The primary focus of these studies was on outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort linked to inflammatory or irritative states.

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

For Seasonal Allergic Rhinitis (hay fever), researchers have conducted RCTs on adults, adolescents, and children (≥ 2 years). Studies examined differences in measured symptom scores, such as sneezing and ocular irritation, using tools like the Total Symptom Score (TSS). Findings describe patterns observed in these symptom measurements. For Perennial Allergic Rhinitis, research explored the compound's effect on persistent nasal and eye symptoms over longer time intervals. Findings indicate that changes in symptom severity scores were observed and monitored throughout the duration of these studies.

Evidence for Use in Chronic Idiopathic Urticaria (Hives)

The compound was studied for Chronic Idiopathic Urticaria (CIU), a condition characterized by recurrent hives and itching. Research utilized controlled studies to explore changes in scores tracking skin pruritus (itching) severity and the physical appearance of the hives in adults and adolescents. Findings describe patterns observed in the studies related to changes in itching scores and the physical size and number of hives during short-term (up to 4–6 week) observation periods. Research provides context on short-term changes in patient-reported discomfort.

Long-Term Studies and Research Gaps

The majority of the evidence comes from trials where follow-up durations are shorter, often lasting only a few weeks to a few months. Research has explored continuous use, but patterns of symptom measurement beyond six months are not fully established by the core clinical trials. Additionally, research exploring how symptoms change over time for severe nasal congestion when the compound is used alone is less extensive. Data for children younger than 2 years with allergic rhinitis remain insufficient from the core clinical program.

Key Studies & References

  1. Loratadine Tablet - DailyMed Label (National Institutes of Health/NIH)

Frequently Asked Questions (FAQ)

Common questions about Alarin (FAQ)


Q: How quickly can I expect to notice a change after starting Alarin?

Regulatory documents describe that the anti-allergic effect of Alarin generally begins within 1 to 3 hours after the first dose. The official information indicates that the medication typically reaches a maximum observed effect within 8 to 12 hours of administration.


Q: Can Alarin affect my mood or mental clarity?

Official safety data lists adverse reactions that relate to the nervous system. Common reactions include Somnolence (drowsiness) and Fatigue. Other reported effects such as Insomnia (difficulty sleeping) and Dizziness are also noted in the official product information.


Q: Is it okay to have coffee or caffeine while taking Alarin?

Official drug documents for the single-ingredient formulation of Alarin typically do not list caffeine as a specific restricted interaction. Regulatory documents advise generally informing a healthcare professional about all other products used, including supplements and over-the-counter medicines.


Q: Are there any long-term effects of taking Alarin that I should know about?

The official overview of the research base notes that the majority of evidence comes from trials lasting a few weeks to a few months. Regulatory documentation indicates that patterns of symptom change beyond six months of continuous use are not fully established by the core clinical trials.


Q: Is Alarin a controlled substance?

Alarin, which contains the active ingredient Loratadine, is not classified as a controlled substance by major governmental drug enforcement or scheduling authorities.


Q: Are there any specific foods I should avoid when using Alarin?

Official regulatory documents state that the medication may be taken with or without food. While food has been observed to increase the amount of active ingredient absorbed by the body, this change is not generally considered clinically significant.


Q: If Alarin stops working, what does that usually mean?

Research has indicated that the active ingredient in Alarin did not show evidence of tolerance to the antihistaminic effect in studies lasting up to 28 days of continuous use. For questions regarding individual changes in response to the medication, the official label directs the reader to consult a healthcare professional.


Q: Can Alarin be taken with supplements or vitamins?

Official documents specifically list interactions with prescription medicines, acetaminophen products, and alcohol. The regulatory label generally advises that individuals inform their healthcare professional about all other products they use, which includes all vitamins, herbal remedies, and supplements.


Q: Is it possible to develop a tolerance to the effects of Alarin?

In clinical studies examining repeated use over 28 days, Alarin did not show evidence of tolerance to the antihistaminic effect. This finding indicates that the intended anti-allergic effect was maintained over the study period.


Q: What is the difference between an allergic reaction and a common side effect of Alarin?

An allergic reaction to Alarin is classified as a Very Rare, serious event (e.g., severe swelling, breathing difficulties, or full body rash) that warrants immediate medical attention. A common side effect is a frequently reported reaction (e.g., headache or fatigue) that is typically mild and does not constitute an emergency.


Q: Can people who drive or operate machinery use Alarin?

The medication is generally described in official summaries as a non-sedating antihistamine. However, since Somnolence (drowsiness) and Dizziness are listed as reported adverse reactions, regulatory documents note that caution may be required for activities like driving or operating machinery until the individual response to the medication is known.


Q: What are the major themes covered in the warnings section of the Alarin official information?

Official documents contain warnings themed around several key risks. These include managing Cumulative Toxicity (risk from combining with other acetaminophen products), heightened Liver Damage Risk (with alcohol or pre-existing severe liver problems), Interference with Diagnostic Tests (requiring discontinuation prior to allergy skin testing), and the risk of Severe Hypersensitivity Reactions.


Q: Can Alarin affect the results of lab tests?

Official documentation specifically requires the medication to be discontinued at least 48 hours prior to allergy skin testing. This step is necessary because the drug may interfere with the test results.


Q: I've heard people talk about a 'crash' when stopping Alarin—what is this?

The regulatory label instructs that treatment discontinuation requires gradual tapering over a minimum of one week. Guidance for this class of drug indicates that abruptly stopping may lead to the re-emergence of symptoms (such as itching or rash) or mild, temporary withdrawal-like symptoms (e.g., dizziness or headache).


Q: What are the most commonly reported less-serious side effects of Alarin?

Based on official safety data, the most frequently reported reactions listed under the 'Common' category (may affect up to 1 in 10 people) are Headache and Somnolence (drowsiness). Fatigue and Insomnia are also listed as common reactions.


Q: Can Alarin cause weight gain or loss?

Official safety documents list Increased Appetite as a Common side effect. Weight Increased is also listed, but its frequency is classified as Not Known, meaning the available data is not sufficient to estimate how often this reaction may occur.


Q: Does Alarin cause dependency or withdrawal symptoms?

Regulatory documents require a gradual tapering process when stopping the medication, which is used to allow for a slow reduction of the active substance. Some medical guidance for this drug class notes that mild, temporary symptoms may be experienced if the medication is stopped abruptly.


Q: Is Alarin available as a generic version?

The active ingredient in Alarin, Loratadine, is widely available globally in non-proprietary (generic) formulations. It can be found under many names in addition to brand-name products.


Q: Why do official documents warn about taking Alarin with grapefruit?

Official sources explain that grapefruit contains substances that can interact with the body's enzyme system responsible for processing the active ingredient. This interaction is described as potentially leading to increased plasma levels of the drug in the bloodstream.


Q: Can Alarin be used in children or teenagers?

Use is established for children aged six years and older. Specific liquid formulations allow for use in children aged two to five years. Use in children younger than two years is generally listed as not established due to insufficient safety and efficacy data from the core clinical program.

How should Alarin be stored and disposed of?

How to Store and Dispose of Alarin

Storage and disposal instructions for Alarin are provided by regulatory bodies to maintain product stability and safety.

Storage Conditions

Alarin must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container, which must remain tightly closed, and be protected from light and excessive moisture. Liquid formulations must not be frozen. Alarin must always be stored out of the sight and reach of children.

Disposal

Unused or expired Alarin should be disposed of using a drug take-back program when available. If a program is not accessible, follow the regulatory procedure of mixing the medicine with an unappealing substance (like dirt or coffee grounds) and sealing it in a container before placing it in the household trash. The product should generally not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Alarin found in:

A-Z Index: